Abstract
The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan. Doses of the two administration forms were chosen as resulting in comparable blood concentrations. Subcutaneous administrations of the drugs were superior for efficacy than the oral forms. This most likely due to a quicker rise in blood concentrations after subcutaneous injections.. In designing new therapies for migraine one should aim at a quick absorption of the drug, which will probably result in an increased efficacy.
Article PDF
References
Thomsen LL, Dixon R, Lassen LH et al (1996) 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270–275, 10.1046/j.1468-2982.1996.1604270.x, 1:STN:280:DyaK28zosVWnsQ%3D%3D, 8792040
Sternieri E, Pinetti D, Coccia CP et al (2005) Pharmacokinetics of sumatriptan in non-responders and in adverse drug reaction reporting migraine patients. J Headache Pain 6:319–321, 10.1007/s10194-005-0220-z, 1:CAS:528:DC%2BD28XmvFGmurs%3D, 16362699
Visser WH, Burggraaf and adverse J, Muller LM et al (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452–460, 10.1016/S0009-9236(96)90202-7, 1:CAS:528:DyaK28XmvFWku7s%3D, 8873693
Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Ed. Philadelphia: Lippincott Williams & Wilkins 469–503
Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287
Tfelt-Hansen P (1993) Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 13:238–244, 10.1046/j.1468-2982.1993.1304238.x, 1:STN:280:DyaK3szos1Ogtw%3D%3D, 8397070
Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10–S19, 10.1111/j.1526-4610.2007.00672.x, 17425704
Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543–548, 10.1007/BF00193709, 1:CAS:528:DyaK2MXmtVWntL8%3D, 7768259
Dahlöf C, Hogenhuis L, Olesen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 5:469–477, 10.1046/j.1468-1331.1998.550469.x, 10210876
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/!D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet 358:1668–1675, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3D, 11728541
International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine. Second edition. Cephalalgia 20:765–786, 10.1046/j.1468-2982.2000.00117.x
Oral Sumatriptan Dose Defining Study Group (1991) Sumatriptan — an oral dose defining study. Eur Neurol 31:300–305, 10.1159/000116632
Mathew NT, Dexter J, Couch J et al (1992) Dose ranging efficacy of safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Study Group. Arch Neurol 49:1271–1276, 1:STN:280:DyaK3s%2FotVCktw%3D%3D, 1333181
Visser WH, Ferrari MD, Bayliss EM et al (1992) Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 12:308–313, 10.1046/j.1468-2982.1992.1205308.x, 1:STN:280:DyaK3s%2Fks1GqsA%3D%3D, 1330318
Havanka H, Dahlöf C, Pop H et al (2000) Efficacy of naratriptan in the acute treatment of migraine: a dose-ranging study. Naratriptan S2BW2004 Study Group. Clin Ther 22:970–980, 10.1016/S0149-2918(00)80068-5, 1:CAS:528:DC%2BD3cXmsFSqtLw%3D, 10972633
Mathew NT, Asgharenjad M, Peykamian M, Laurenza A (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49:485–490
Klassen A, Elkind A, Asgharnejad M et al (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 37:640–645, 10.1046/j.1526-4610.1997.3710640.x, 1:STN:280:DyaK1c7gt1SksA%3D%3D, 9439085
Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. Cephalalgia, in press
Volans GN (1974) Absorption of effervescent aspirin during migraine. BMJ 4:265–269, 10.1136/bmj.4.5939.265, 1:STN:280:DyaE2M%2Fjs1yjsQ%3D%3D, 4425854
Tfelt-Hansen P, Young WB, Silberstein SD (2006) Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Eds. Philadelphia: Lippincott Williams & Wilkins 505–513
Jhee SS, Shiovitz T, Crawford AW, Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 40:189–205
Sumatriptan Cluster Headache Study Group (1991) Treatment for acute cluster headache with sumatriptan. N Eng J Med 325:322–326, 10.1056/NEJM199108013250505
Connor HE, Feniuk W, Beattie DT et al (1997) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 17:145–152, 10.1046/j.1468-2982.1997.1703145.x, 1:STN:280:DyaK2szhtl2gtw%3D%3D, 9170336
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Tfelt-Hansen, P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8, 273–276 (2007). https://doi.org/10.1007/s10194-007-0411-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10194-007-0411-x